Candel Therapeutics (CADL)
Candel Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
12.8M
Short interest
settlement 2026-10-15
14.1
Days to cover
+2.9 days vs prior
86.8%
Short share of volume
2026-11-03
21,218
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
-$3.2M
Insider flow, 90 days
0 buys, 3 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CADL is 12,772,884 shares, up 428,235 shares over the last month. Over the last 48 readings it ranged from 1,779,737 shares (31 October 2024) to 16,135,706 shares (30 June 2026). At the reported average volume of 907K shares a day that is 14.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cadl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 12,772,884 | -1.8% | 907,006 | 14.08 |
| 2026-09-30 | 13,000,504 | +5.3% | 1,165,450 | 11.15 |
| 2026-09-15 | 12,344,649 | +0.7% | 1,201,218 | 10.28 |
| 2026-08-31 | 12,265,275 | -1.6% | 1,334,072 | 9.19 |
| 2026-08-14 | 12,463,333 | -1.5% | 1,180,656 | 10.56 |
| 2026-07-31 | 12,655,457 | -2.4% | 1,215,993 | 10.41 |
| 2026-07-15 | 12,961,675 | -19.7% | 1,438,489 | 9.01 |
| 2026-06-30 | 16,135,706 | +18.5% | 2,697,760 | 5.98 |
| 2026-06-15 | 13,617,030 | -3.9% | 1,797,046 | 7.58 |
| 2026-05-29 | 14,163,766 | -1.8% | 1,854,979 | 7.64 |
| 2026-05-15 | 14,424,891 | -1.8% | 2,601,558 | 5.54 |
| 2026-04-30 | 14,681,430 | -2.6% | 2,289,498 | 6.41 |
| 2026-04-15 | 15,067,083 | +1.7% | 971,257 | 15.51 |
| 2026-03-31 | 14,816,272 | +4.5% | 1,265,277 | 11.71 |
| 2026-03-13 | 14,182,716 | +9.2% | 1,275,494 | 11.12 |
| 2026-02-27 | 12,985,515 | +39.7% | 1,921,439 | 6.76 |
| 2026-02-13 | 9,295,851 | -0.7% | 584,101 | 15.91 |
| 2026-01-30 | 9,356,491 | +0.4% | 743,077 | 12.59 |
| 2026-01-15 | 9,323,140 | +1.4% | 718,793 | 12.97 |
| 2025-12-31 | 9,190,578 | +10.4% | 630,229 | 14.58 |
| 2025-12-15 | 8,327,222 | +0.7% | 1,256,478 | 6.63 |
| 2025-11-28 | 8,272,637 | -0.9% | 696,763 | 11.87 |
| 2025-11-14 | 8,344,526 | +11.6% | 632,705 | 13.19 |
| 2025-10-31 | 7,479,907 | +0.1% | 713,961 | 10.48 |
| 2025-10-15 | 7,473,390 | +3.5% | 971,994 | 7.69 |
| 2025-09-30 | 7,222,409 | -2.9% | 756,949 | 9.54 |
| 2025-09-15 | 7,434,796 | +2.3% | 922,413 | 8.06 |
| 2025-08-29 | 7,270,816 | +7.8% | 527,598 | 13.78 |
| 2025-08-15 | 6,742,773 | +4.3% | 633,102 | 10.65 |
| 2025-07-31 | 6,464,874 | -1.4% | 880,483 | 7.34 |
| 2025-07-15 | 6,555,372 | -0.4% | 1,123,600 | 5.83 |
| 2025-06-30 | 6,580,198 | +5.1% | 1,040,002 | 6.33 |
| 2025-06-13 | 6,259,547 | +6.3% | 813,541 | 7.69 |
| 2025-05-30 | 5,885,529 | -5.3% | 1,110,695 | 5.30 |
| 2025-05-15 | 6,217,963 | +15.3% | 861,988 | 7.21 |
| 2025-04-30 | 5,391,333 | +6.9% | 912,040 | 5.91 |
| 2025-04-15 | 5,044,330 | +12.9% | 954,740 | 5.28 |
| 2025-03-31 | 4,467,530 | +29.4% | 1,274,181 | 3.51 |
| 2025-03-14 | 3,451,955 | +3.5% | 809,409 | 4.26 |
| 2025-02-28 | 3,336,698 | -3.2% | 2,056,189 | 1.62 |
| 2025-02-14 | 3,447,712 | +30.4% | 861,811 | 4.00 |
| 2025-01-31 | 2,643,545 | -9.6% | 921,772 | 2.87 |
| 2025-01-15 | 2,923,822 | -4.5% | 1,689,907 | 1.73 |
| 2024-12-31 | 3,060,269 | -33.0% | 4,085,434 | 1.00 |
| 2024-12-13 | 4,567,920 | +109.6% | 15,267,542 | 1.00 |
| 2024-11-29 | 2,179,182 | +3.9% | 702,039 | 3.10 |
| 2024-11-15 | 2,096,617 | +17.8% | 347,480 | 6.03 |
| 2024-10-31 | 1,779,737 | +8.5% | 247,334 | 7.20 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of CADL volume is 86.8%, up 42.7 points over the last five sessions. Over the last 30 readings it ranged from 39.0% (2 November 2026) to 86.8% (3 November 2026). The latest reading sits at the top of that range. The latest reading is 30.8 points above the 30-session average of 56.0%, on 1.8M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 1.6M | 1.8M | 86.8% | 1,775 |
| 2026-11-02 | 135K | 345K | 39.0% | 1,937 |
| 2026-10-30 | 173K | 307K | 56.3% | 0 |
| 2026-10-29 | 191K | 312K | 61.2% | 0 |
| 2026-10-28 | 120K | 238K | 50.3% | 0 |
| 2026-10-27 | 168K | 381K | 44.1% | 0 |
| 2026-10-26 | 206K | 380K | 54.1% | 51 |
| 2026-10-23 | 296K | 514K | 57.6% | 236 |
| 2026-10-22 | 168K | 290K | 58.0% | 24 |
| 2026-10-21 | 215K | 442K | 48.7% | 11 |
| 2026-10-20 | 291K | 428K | 68.0% | 242 |
| 2026-10-19 | 268K | 433K | 61.9% | 466 |
| 2026-10-16 | 377K | 690K | 54.6% | 249 |
| 2026-10-15 | 202K | 436K | 46.3% | 748 |
| 2026-10-14 | 164K | 338K | 48.5% | 0 |
| 2026-10-13 | 261K | 510K | 51.1% | 156 |
| 2026-10-12 | 165K | 280K | 58.7% | 259 |
| 2026-10-09 | 221K | 295K | 75.1% | 0 |
| 2026-10-08 | 189K | 338K | 55.9% | 2,787 |
| 2026-10-07 | 153K | 299K | 51.3% | 0 |
| 2026-10-06 | 222K | 395K | 56.2% | 1,112 |
| 2026-10-05 | 159K | 357K | 44.6% | 0 |
| 2026-10-02 | 217K | 355K | 61.1% | 16 |
| 2026-10-01 | 216K | 376K | 57.4% | 100 |
| 2026-09-30 | 255K | 510K | 50.0% | 4,002 |
| 2026-09-29 | 198K | 413K | 47.9% | 0 |
| 2026-09-28 | 195K | 305K | 63.8% | 100 |
| 2026-09-25 | 233K | 382K | 61.1% | 178 |
| 2026-09-24 | 217K | 379K | 57.3% | 0 |
| 2026-09-23 | 244K | 452K | 53.8% | 3,536 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in CADL is 21,218 shares, up 20,641 shares over the last settlement date. Over the last 30 readings it ranged from 64 shares (25 August 2026) to 117,062 shares (11 September 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 21,218 | $9.27 | $197K |
| 2026-09-24 | 577 | $11.29 | $7K |
| 2026-09-22 | 280 | $11.21 | $3K |
| 2026-09-21 | 46,353 | $10.85 | $503K |
| 2026-09-16 | 3,104 | $11.12 | $35K |
| 2026-09-11 | 117,062 | $11.33 | $1.3M |
| 2026-09-09 | 11,645 | $12.60 | $147K |
| 2026-09-08 | 193 | $12.78 | $2K |
| 2026-09-03 | 26,298 | $13.20 | $347K |
| 2026-08-28 | 6,804 | $13.75 | $94K |
| 2026-08-25 | 64 | $12.86 | $823 |
| 2026-08-24 | 9,382 | $13.13 | $123K |
| 2026-08-13 | 95 | $10.68 | $1K |
| 2026-08-06 | 121 | $10.46 | $1K |
| 2026-08-04 | 7,314 | $10.07 | $74K |
| 2026-07-30 | 1,000 | $9.40 | $9K |
| 2026-07-29 | 679 | $9.68 | $7K |
| 2026-07-28 | 3,560 | $9.96 | $35K |
| 2026-07-27 | 7,452 | $9.56 | $71K |
| 2026-07-24 | 15,198 | $9.86 | $150K |
| 2026-07-22 | 17,318 | $10.22 | $177K |
| 2026-07-20 | 4,475 | $10.18 | $46K |
| 2026-07-16 | 1,485 | $9.64 | $14K |
| 2026-07-15 | 12,014 | $9.87 | $119K |
| 2026-07-14 | 134 | $9.64 | $1K |
| 2026-07-10 | 12,202 | $9.89 | $121K |
| 2026-07-09 | 408 | $9.88 | $4K |
| 2026-07-08 | 4,181 | $9.85 | $41K |
| 2026-07-07 | 49,755 | $10.03 | $499K |
| 2026-07-02 | 2,289 | $9.88 | $23K |
Insider trades
SEC Form 4, newest first. JSONInsiders at CADL reported 3 open-market sells worth $3.2M in the last 90 days and no open-market buys. Latest filing: Tak Paul Peter (Chief Executive Officer) on 2026-09-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Tak Paul Peter | Chief Executive Officer | Sell | 59K | $10.46 | $621K | 113K |
| 2026-09-10 | Tak Paul Peter | Chief Executive Officer | Sell | 221K | $11.50 | $2.5M | 173K |
| 2026-09-10 | Tak Paul Peter | Chief Executive Officer | Exercise or conversion | 125K | $1.55 | $194K | 394K |
| 2026-08-17 | Tyagarajan Seshu | Chief Technology Officer | Sell | 7K | $12.00 | $84K | 77K |
| 2026-06-29 | Tyagarajan Seshu | Chief Technology Officer | Sell | 7K | $10.02 | $70K | 84K |
| 2026-06-29 | Barone Francesca | Chief Scientific Officer | Sell | 23K | $10.06 | $236K | 77K |
| 2026-02-23 | Manning Paul B | Director | Buy | 550K | $5.45 | $3.0M | 2.8M |
| 2025-07-28 | Nichols William Garrett | Chief Medical Officer | Sell | 937 | $6.98 | $7K | 52K |
| 2025-07-28 | Nichols William Garrett | Chief Medical Officer | Exercise or conversion | 937 | $1.29 | $1K | 53K |
| 2025-06-30 | Nichols William Garrett | Chief Medical Officer | Sell | 781 | $5.04 | $4K | 52K |
| 2025-06-30 | Nichols William Garrett | Chief Medical Officer | Exercise or conversion | 781 | $1.29 | $1K | 53K |
| 2025-06-25 | Tyagarajan Seshu | Chief Technology Officer | Grant | 5K | $4.67 | $25K | 91K |
| 2025-06-25 | Tak Paul Peter | Chief Executive Officer | Grant | 43K | $4.67 | $200K | 269K |
| 2025-06-25 | Manning Paul B | Director | Grant | 1.1M | $4.67 | $5.0M | 2.2M |
| 2025-06-25 | Martell Christopher | Director | Grant | 111K | $4.67 | $520K | 111K |
| 2025-06-25 | Loggia Nicoletta | Director | Grant | 2K | $4.67 | $10K | 2K |
| 2025-06-25 | Schoch Charles | Chief Financial Officer | Grant | 5K | $4.67 | $25K | 43K |
| 2025-06-25 | Nabel Gary J. | Director | Grant | 5K | $4.67 | $25K | 5K |
| 2025-06-25 | PAPA JOSEPH C | Director | Grant | 64K | $4.67 | $300K | 64K |
| 2025-06-25 | Barone Francesca | Chief Scientific Officer | Grant | 4K | $4.67 | $20K | 101K |
| 2025-03-19 | Tak Paul Peter | Chief Executive Officer | Sell | 400 | $9.00 | $4K | 226K |
| 2025-03-18 | Tak Paul Peter | Chief Executive Officer | Sell | 26K | $8.77 | $226K | 226K |
| 2025-03-18 | Barone Francesca | Chief Scientific Officer | Sell | 32K | $8.76 | $282K | 97K |
| 2025-03-18 | Barone Francesca | Chief Scientific Officer | Exercise or conversion | 18K | $1.55 | $28K | 129K |
| 2025-03-18 | Nichols William Garrett | Chief Medical Officer | Sell | 45K | $8.76 | $397K | 52K |
| 2025-03-18 | Nichols William Garrett | Chief Medical Officer | Exercise or conversion | 14K | $1.29 | $18K | 98K |
| 2025-03-18 | Nichols William Garrett | Chief Medical Officer | Exercise or conversion | 5K | $3.75 | $17K | 84K |
| 2025-03-17 | Schoch Charles | See Remarks | Sell | 5K | $8.83 | $44K | 38K |
| 2025-03-17 | Tyagarajan Seshu | Chief Technology Officer | Exercise or conversion | 20K | $1.29 | $26K | 117K |
| 2025-03-17 | Tyagarajan Seshu | Chief Technology Officer | Sell | 31K | $8.82 | $276K | 86K |
| 2025-02-21 | Aguilar-Cordova Estuardo | TenPercentOwner | Returned to company | 11K | $12.02 | $127K | 121K |
| 2025-02-21 | Aguilar-Cordova Estuardo | TenPercentOwner | Returned to company | 11K | $12.02 | $127K | 163K |
| 2025-02-10 | Aguilar-Cordova Estuardo | TenPercentOwner | Returned to company | 31K | $8.61 | $270K | 60K |
| 2025-01-15 | Nichols William Garrett | Chief Medical Officer | Sell | 10K | $7.23 | $75K | 79K |
| 2025-01-15 | Tak Paul Peter | Chief Executive Officer | Sell | 22K | $7.23 | $157K | 252K |
| 2025-01-15 | Schoch Charles | See Remarks | Sell | 10K | $7.23 | $69K | 43K |
| 2025-01-15 | Barone Francesca | Chief Scientific Officer | Sell | 14K | $7.23 | $98K | 111K |
| 2025-01-15 | Tyagarajan Seshu | Chief Technology Officer | Sell | 14K | $7.23 | $104K | 97K |
| 2025-01-08 | Nichols William Garrett | Chief Medical Officer | Sell | 11K | $8.22 | $89K | 90K |
| 2025-01-08 | Tyagarajan Seshu | Chief Technology Officer | Sell | 15K | $8.22 | $120K | 111K |
| 2025-01-08 | Tak Paul Peter | Chief Executive Officer | Sell | 21K | $8.22 | $174K | 274K |
| 2025-01-08 | Schoch Charles | See Remarks | Sell | 10K | $8.22 | $82K | 53K |
| 2025-01-08 | Barone Francesca | Chief Scientific Officer | Sell | 14K | $8.22 | $112K | 124K |
| 2024-12-27 | Aguilar Laura K. | TenPercentOwner | Returned to company | 50K | $8.85 | $443K | 174K |
| 2024-12-26 | Aguilar Laura K. | TenPercentOwner | Returned to company | 50K | $9.01 | $451K | 224K |
| 2024-12-24 | Aguilar Laura K. | TenPercentOwner | Returned to company | 50K | $8.82 | $441K | 274K |
| 2024-12-23 | Aguilar Laura K. | TenPercentOwner | Returned to company | 50K | $8.52 | $426K | 324K |
| 2024-12-20 | Aguilar Laura K. | TenPercentOwner | Returned to company | 100K | $9.00 | $900K | 331K |
| 2024-12-16 | Manning Paul B | Director | Buy | 750K | $6.00 | $4.5M | 1.3M |
| 2024-12-16 | Manning Paul B | Director | Buy | 500K | $6.00 | $3.0M | 1.1M |
| 2024-12-12 | Aguilar-Cordova Estuardo | 10% owner | Returned to company | 200K | $10.04 | $2.0M | 474K |
| 2024-12-12 | Aguilar-Cordova Estuardo | TenPercentOwner | Returned to company | 200K | $10.04 | $2.0M | 431K |
| 2024-12-11 | Aguilar-Cordova Estuardo | 10% owner | Returned to company | 200K | $8.53 | $1.7M | 631K |
| 2024-12-11 | Aguilar-Cordova Estuardo | TenPercentOwner | Returned to company | 200K | $8.53 | $1.7M | 674K |
| 2024-12-06 | Aguilar Laura K. | TenPercentOwner | Returned to company | 20K | $5.23 | $105K | 91K |
| 2024-12-05 | Aguilar Laura K. | TenPercentOwner | Returned to company | 20K | $4.79 | $96K | 111K |
| 2024-12-04 | Aguilar Laura K. | TenPercentOwner | Returned to company | 20K | $4.46 | $89K | 131K |
| 2024-11-29 | Barone Francesca | Chief Scientific Officer | Sell | 22K | $4.56 | $101K | 138K |
| 2024-11-29 | Nichols William Garrett | Chief Medical Officer | Sell | 14K | $4.56 | $64K | 101K |
| 2024-11-29 | Tak Paul Peter | Chief Executive Officer | Sell | 49K | $4.56 | $223K | 295K |
| 2024-11-29 | Tyagarajan Seshu | Chief Technology Officer | Sell | 20K | $4.56 | $93K | 126K |
| 2024-11-25 | Aguilar Laura K. | TenPercentOwner | Returned to company | 20K | $4.97 | $99K | 151K |
| 2024-11-21 | Tak Paul Peter | Chief Executive Officer | Exercise or conversion | 13K | $1.55 | $20K | 344K |
| 2024-11-08 | Aguilar Laura K. | TenPercentOwner | Returned to company | 8K | $4.92 | $37K | 831K |
| 2024-11-07 | Aguilar Laura K. | TenPercentOwner | Returned to company | 8K | $5.19 | $39K | 839K |
| 2024-11-06 | Aguilar Laura K. | TenPercentOwner | Returned to company | 8K | $5.33 | $40K | 889K |
| 2024-11-01 | Aguilar Laura K. | TenPercentOwner | Returned to company | 8K | $5.27 | $40K | 896K |
| 2024-10-31 | Aguilar Laura K. | TenPercentOwner | Returned to company | 8K | $5.30 | $40K | 904K |
| 2024-10-30 | Aguilar Laura K. | TenPercentOwner | Returned to company | 6K | $5.38 | $32K | 911K |
| 2024-10-28 | Aguilar Laura K. | TenPercentOwner | Returned to company | 12K | $5.58 | $65K | 889K |
| 2024-10-25 | Aguilar Laura K. | TenPercentOwner | Returned to company | 2K | $5.80 | $9K | 900K |
| 2024-10-24 | Aguilar Laura K. | TenPercentOwner | Returned to company | 1K | $5.72 | $7K | 902K |
| 2024-10-24 | Aguilar Laura K. | TenPercentOwner | Returned to company | 16K | $5.53 | $91K | 903K |
| 2024-10-15 | Aguilar-Cordova Estuardo | TenPercentOwner | Sell | 10K | $6.03 | $63K | 919K |
| 2024-10-14 | Aguilar-Cordova Estuardo | TenPercentOwner | Sell | 15K | $6.02 | $90K | 930K |
| 2024-10-11 | Aguilar-Cordova Estuardo | TenPercentOwner | Sell | 15K | $6.05 | $91K | 945K |
| 2024-10-03 | Aguilar-Cordova Estuardo | TenPercentOwner | Sell | 2K | $6.85 | $12K | 960K |
| 2024-10-02 | Aguilar-Cordova Estuardo | TenPercentOwner | Sell | 27K | $6.92 | $187K | 962K |
| 2024-10-01 | Aguilar-Cordova Estuardo | TenPercentOwner | Sell | 6K | $7.01 | $44K | 989K |
| 2024-07-17 | Barone Francesca | Chief Scientific Officer | Sell | 14K | $6.47 | $91K | 160K |
| 2024-07-17 | Nichols William Garrett | Chief Medical Officer | Sell | 11K | $6.47 | $70K | 114K |
| 2024-07-17 | Schoch Charles | See Remarks | Sell | 10K | $6.47 | $64K | 63K |
| 2024-07-17 | Tak Paul Peter | Chief Executive Officer | Sell | 23K | $6.47 | $146K | 331K |
| 2024-07-17 | Tyagarajan Seshu | Chief Technology Officer | Sell | 15K | $6.47 | $96K | 146K |
| 2024-07-11 | Barone Francesca | Chief Scientific Officer | Sell | 13K | $5.97 | $75K | 174K |
| 2024-07-11 | Nichols William Garrett | Chief Medical Officer | Sell | 10K | $5.97 | $58K | 125K |
| 2024-07-11 | Schoch Charles | See Remarks | Sell | 9K | $5.97 | $53K | 72K |
| 2024-07-11 | Tak Paul Peter | Chief Executive Officer | Sell | 20K | $5.97 | $121K | 353K |
| 2024-07-11 | Tyagarajan Seshu | Chief Technology Officer | Sell | 13K | $5.97 | $80K | 161K |
| 2023-11-28 | Amello Jason | Chief Financial Officer | Tax withholding | 20K | $0.90 | $18K | 202K |
| 2023-11-28 | Barone Francesca | Chief Scientific Officer | Tax withholding | 20K | $0.90 | $18K | 187K |
| 2023-11-28 | Tyagarajan Seshu | Chief Technology Officer | Tax withholding | 17K | $0.90 | $16K | 174K |
| 2023-11-28 | Nichols William Garrett | Chief Medical Officer | Tax withholding | 12K | $0.90 | $11K | 135K |
| 2023-11-28 | Tak Paul Peter | Chief Executive Officer | Tax withholding | 43K | $0.90 | $39K | 374K |
| 2023-11-26 | Tak Paul Peter | Chief Executive Officer | Grant | 180K | $0.00 | $0 | 417K |
| 2023-11-26 | Amello Jason | Chief Financial Officer | Grant | 126K | $0.00 | $0 | 222K |
| 2023-11-26 | Tyagarajan Seshu | Chief Technology Officer | Grant | 105K | $0.00 | $0 | 192K |
| 2023-11-26 | Nichols William Garrett | Chief Medical Officer | Grant | 89K | $0.00 | $0 | 147K |
| 2023-11-26 | Barone Francesca | Chief Scientific Officer | Grant | 113K | $0.00 | $0 | 206K |
| 2022-12-09 | Tak Paul Peter | Chief Executive Officer | Buy | 13K | $1.92 | $25K | 41K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for CADL worth $3.8M at the prices reported; 2 in the last 90 days worth $3.5M. Latest: PAUL PETER TAK filed on 2026-09-10 to sell 280,245 shares ($3.4M) from 2026-09-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-10 | PAUL PETER TAKDirector, Officer | 280K | $3.4M | 0.366% | 2026-09-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | SESHU TYAGARAJANOfficer | 7K | $82K | 0.009% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | SESHU P TYAGARAJANOfficer | 7K | $69K | 0.010% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-29 | FRANCESCA BARONEOfficer | 23K | $230K | 0.032% | 2026-06-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of CADL in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is RTW Investments, LP at 8.8% of the class (6,422,018 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 4.8M | 6.6% | 2026-06-30 |
| 2026-05-15 | 13G | RTW Investments, LPinvestment adviser, partnership | 6.4M | 8.8% | 2026-03-31 |
| 2026-05-15 | 13G | Roderick Wongparent holding company, individual | 6.4M | 8.8% | 2026-03-31 |
| 2026-03-18 | 13D/Ano. 1 | Paul B Manningindividual | 5.8M | 7.9% | 2024-12-16 |
| 2026-03-18 | 13D/Ano. 1 | The Paul B. Manning Revocable Trust dated May 10, 2000other entity | 2.8M | 3.8% | 2024-12-16 |
| 2026-03-18 | 13D/Ano. 1 | BKB Growth Investments, LLCother entity | 1.3M | 1.8% | 2024-12-16 |
13F holders
Tracked managers holding CADL at their latest 13F. JSON7 of the 30 tracked managers held CADL at their latest 13F, $16.4M in total at quarter-end prices. Millennium Management is the largest at $11.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.1M | $11.3M | 0.00% | +34K |
| Citadel Advisors | 2026-06-30 | 146K | $1.5M | 0.00% | +73K |
| Point72 Asset Management | 2026-06-30 | 129K | $1.3M | 0.00% | +22K |
| D. E. Shaw & Co. | 2026-06-30 | 109K | $1.1M | 0.00% | new |
| Fisher Asset Management | 2026-06-30 | 58K | $595K | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 33K | $337K | 0.00% | -61K |
| AQR Capital Management | 2026-06-30 | 20K | $210K | 0.00% | +2K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Candel Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Candel Therapeutics (CADL), SEC CIK 1841387, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1841387Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of CADL is sold short?
12,772,884 shares were held short at the 2026-10-15 settlement, 14.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CADL's daily short volume?
On 2026-11-03, 1,603,623 of the 1,847,211 CADL shares reported to FINRA were sold short, 86.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CADL have fails to deliver?
The SEC's latest file shows 21,218 CADL shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are CADL insiders buying or selling?
Insiders at CADL reported 3 open-market sells worth $3.2M in the last 90 days and no open-market buys. Latest filing: Tak Paul Peter (Chief Executive Officer) on 2026-09-11.
Have CADL insiders filed to sell?
4 Form 144 notices on file for CADL worth $3.8M at the prices reported; 2 in the last 90 days worth $3.5M. Latest: PAUL PETER TAK filed on 2026-09-10 to sell 280,245 shares ($3.4M) from 2026-09-10.
Who owns 5% or more of CADL?
4 holders report 5% or more of CADL in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is RTW Investments, LP at 8.8% of the class (6,422,018 shares), filed 2026-05-15 for an event on 2026-03-31.
Which tracked 13F managers own CADL?
7 of the 30 tracked 13F managers held CADL shares at their latest filing, $16.4M in all. The largest: Izzy Englander's Millennium Management (1.1M shares, $11.3M), Ken Griffin's Citadel Advisors (146K shares, $1.5M), Steve Cohen's Point72 Asset Management (129K shares, $1.3M), D. E. Shaw & Co. (109K shares, $1.1M), Ken Fisher's Fisher Asset Management (58K shares, $595K), Two Sigma Investments (33K shares, $337K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.